Value-based pricing needs to be transparent, says Bayer Schering Pharma's CEO
This article was originally published in Scrip
Executive Summary
Andreas Fibig, the CEO of Bayer Schering Pharma, says that as long as the new value-based pricing (VBP) concept that the UK government is proposing is transparent for the industry, he has no issue whether it is NICE, the health technology assessment agency for England and Wales, or another body that should be involved in setting drug prices. He was talking as a panellist at Scrip's round table on "payer strategies" (scripintelligence.com/roundtable).